Sold as Spectrobid. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Bacampicillin Hydrochloride (sold as Spectrobid), first approved Dec 22, 1980, with 0 new uses approved and 0 published complete response letters.
| Dec 22, 1980 | SpectrobidNDA 50520 · New molecular entity | Pfizer | 10 | Discontinued |
| Mar 23, 1982 | SpectrobidNDA 50556 · New dosage form | Pfizer | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Pfizer